Gary D. Steinberg, MD
Professor, Department of Urology, Rush University
Gary D. Steinberg, MD
Scientific Advisory Board, Vesica Health
Dr. Steinberg was previously the Director of the Bladder Cancer program at New York University and formerly the Director of Urologic Oncology at the University of Chicago. He is the immediate past Chairperson of the Scientific Advisory Board of the Bladder Cancer Advocacy Network and serves on the executive committee of the Bladder Cancer Research Network. Dr. Steinberg has been on multiple panels for the FDA and NCI and helped create the guidelines for immunotherapy of bladder cancer for the Society of Immunotherapy of Cancer (SITC). He is a member of the American Urological Association (AUA), Society of Urologic Oncology (SUO), International Bladder Cancer Group (IBCG), and the Bladder Cancer Advocacy Network (BCAN).
Â
Dr. Steinberg is a recognized expert in translational bladder cancer research and innovative clinical trials. He is a pioneer in the use of blue light cystoscopy to detect and remove early-stage bladder cancer and has been instrumental in developing innovative surgical procedures for patients with bladder cancer. A prolific researcher, Dr. Steinberg has made significant contributions to our understanding of non-muscle invasive and muscle-invasive bladder cancer and serves as the principal investigator on numerous clinical trials, working to identify new novel therapies and molecular biomarkers to detect the disease. He is involved with innovative intravesical drug delivery systems and novel neoadjuvant and adjuvant therapy trials. Dr. Steinberg is currently leading the development of personalized cancer vaccines for neoadjuvant and metastatic bladder cancer.